ArticleEuropean radiology2025
External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound.
Article in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Prostate specific membrane antigen focal ablation imaging (PSMA-FAB).Prostate cancer and prostatic diseases · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThe efficacy of focal therapy (FT) has improved with the use of multiparametric MRI (mpMRI) for lesion identification, though standardized mpMRI reporting post-FT is lacking. The Prostate Imaging after Focal Ablation (PI-FAB) scoring system was recently introduced to standardize mpMRI interpretation for local recurrence post-FT. This study evaluates the diagnostic performance and inter-reader reliability of PI-FAB following cryoablation and high-intensity focused ultrasound (HIFU) modalities. MATERIALS AND
methodsThis retrospective, single-institution study included all patients treated with FT from 2007 to 2023 with available follow-up mpMRI and subsequent prostate biopsy. Three fellowship-trained radiologists scored these images using the PI-FAB system. The primary objective was inter-reader agreeability of PI-FAB scores, and the secondary objective assessed performance metrics, including sensitivity, specificity, positive predictive and negative predictive value.
results91 patients with 113 mpMRI exams (95 post-cryotherapy; 18 post-HIFU) were reviewed. There was substantial agreement between the readers (Fleiss' Kappa (κ): 0.71, p < 0.001; Gwet AC2: 0.70, p < 0.03). A PI-FAB score 3 had a significant ability to rule-in csPCa with high specificity (88%, 86%, and 93% per reader, respectively), and PI-FAB score 1 had high sensitivity to rule out csPCa (88%, 78%, and 84% per reader, respectively) in surveillance imaging (14-16 months median follow-up).
conclusionsOur study suggests that the PI-FAB scoring system can be effectively used to evaluate mpMRI recurrence post-FT, with substantial inter-reader reliability and high specificity for predicting in-field clinically significant prostate cancer recurrence post-cryotherapy and HIFU. Larger, multi-institutional studies are essential to confirm PI-FAB's utility in clinical practice. KEY POINTS: Question There is no widely accepted and validated standardized scoring system to predict the local recurrence of clinically significant prostate cancer after focal therapy with ablative modalities. Findings The Prostate Imaging after Focal Ablation (PI-FAB) scoring system effectively predicts in-field recurrence of prostate cancer after focal therapy with substantial inter-reader reliability and specificity. Clinical relevance As patient requests for focal therapy to treat localized low- to- intermediate risk prostate cancer become more common, based on its performance metrics, PI-FAB will aid in identifying in-field recurrence within this patient population.
Indexed as
Identifiers
40172640What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.